MX2021015854A - Composiciones y métodos para tratar trastornos del snc. - Google Patents

Composiciones y métodos para tratar trastornos del snc.

Info

Publication number
MX2021015854A
MX2021015854A MX2021015854A MX2021015854A MX2021015854A MX 2021015854 A MX2021015854 A MX 2021015854A MX 2021015854 A MX2021015854 A MX 2021015854A MX 2021015854 A MX2021015854 A MX 2021015854A MX 2021015854 A MX2021015854 A MX 2021015854A
Authority
MX
Mexico
Prior art keywords
compounds
cns disorders
treating cns
compound
formula
Prior art date
Application number
MX2021015854A
Other languages
English (en)
Inventor
Francesco G Salituro
Maria Jesus Blanco-Pillado
Marshall Lee Morningstart
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Publication of MX2021015854A publication Critical patent/MX2021015854A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/002—Expansion of ring A by one atom, e.g. A homo steroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0059—Estrane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/008—Ketals at position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0044—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 with an estrane or gonane skeleton, including 18-substituted derivatives and derivatives where position 17-beta is substituted by a carbon atom not directly bonded to another carbon atom and not being part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Abstract

En el presente documento se proporciona, en parte, un compuesto de Fórmula I: (ver formula) o una sal farmacéuticamente aceptable de este, composiciones farmacéuticas que comprenden un compuesto de Fórmula I y métodos de uso de los compuestos, p. ej., en el tratamiento de trastornos del SNC.
MX2021015854A 2019-06-27 2020-06-29 Composiciones y métodos para tratar trastornos del snc. MX2021015854A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962867736P 2019-06-27 2019-06-27
US201962867734P 2019-06-27 2019-06-27
US201962867695P 2019-06-27 2019-06-27
PCT/US2020/040164 WO2020264512A1 (en) 2019-06-27 2020-06-29 Compounds for treating cns disorders

Publications (1)

Publication Number Publication Date
MX2021015854A true MX2021015854A (es) 2022-04-18

Family

ID=71728948

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021015854A MX2021015854A (es) 2019-06-27 2020-06-29 Composiciones y métodos para tratar trastornos del snc.

Country Status (10)

Country Link
US (1) US20230257415A1 (es)
EP (1) EP3990468A1 (es)
JP (1) JP2022538301A (es)
CN (1) CN114729000A (es)
AU (1) AU2020304679A1 (es)
BR (1) BR112021026445A2 (es)
CA (1) CA3143545A1 (es)
MX (1) MX2021015854A (es)
TW (1) TW202114695A (es)
WO (1) WO2020264512A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
ES2793237T3 (es) 2014-11-27 2020-11-13 Sage Therapeutics Inc Composiciones y métodos para el tratamiento de trastornos del SNC
BR112021009428A2 (pt) 2018-10-12 2021-08-31 Sage Therapeutics, Inc. Esteroides neuroativos substituídos na posição 10 por um grupo cíclico para uso no tratamento de distúrbios do cns
JP2022510683A (ja) 2018-12-05 2022-01-27 セージ セラピューティクス， インコーポレイテッド 神経刺激性ステロイド及びその使用方法
CN116059215A (zh) * 2019-01-08 2023-05-05 成都康弘药业集团股份有限公司 甾体类化合物、用途及其制备方法
MA56046A (fr) 2019-05-31 2022-04-06 Sage Therapeutics Inc Stéroïdes neuroactifs et compositions associées

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2969M (fr) * 1963-05-22 1964-11-30 Roussel Uclaf Nouveau médicament notamment pour le traitement des spasmes d'origine coronarienne on viscérale.
DK134348C (da) * 1973-11-30 1977-03-21 Schering Ag Analogifremgangsmade til fremstilling af d-homo-20-ketopregnaner
IL48628A0 (en) * 1974-12-23 1976-02-29 Schering Ag D-homo-20-keto-pregnanes and process for their manufactur
GB1570394A (en) * 1976-01-06 1980-07-02 Glaxo Lab Ltd 11-acyloxy-3-hydroxy steroids
GB1581234A (en) * 1976-04-05 1980-12-10 Glaxo Operations Ltd 11a - amino - 3a - hydroxysteroids
GB1581235A (en) * 1977-04-04 1980-12-10 Glaxo Operations Ltd 11a-amino-3a-hydroxy-steroids
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
DE69519945T2 (de) * 1994-11-23 2001-06-07 Cocensys Inc Androstan- und pregnanserien für die allosterische modulation des gaba-rezeptors
WO1998005337A1 (en) * 1996-08-01 1998-02-12 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
PT3498725T (pt) 2013-04-17 2021-09-09 Sage Therapeutics Inc Esteroides c21-n-pirazolilo 19-nor c3,3-dissubstituídos para uso em terapia
DK3258939T3 (da) 2015-02-20 2022-12-12 Sage Therapeutics Inc Neuroaktive steroider, sammensætninger og anvendelser heraf
IL264129B1 (en) 2016-07-11 2024-01-01 Sage Therapeutics Inc C20, C17 and C21 converted neuroactive steroids and methods of using them
EP3728285A1 (en) 2017-12-22 2020-10-28 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
EP3750908A4 (en) * 2018-02-11 2022-07-27 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. STEROID DERIVATIVE REGULATORS, PROCESSES FOR THEIR PREPARATION AND THEIR USES
JP2022510683A (ja) * 2018-12-05 2022-01-27 セージ セラピューティクス， インコーポレイテッド 神経刺激性ステロイド及びその使用方法

Also Published As

Publication number Publication date
EP3990468A1 (en) 2022-05-04
TW202114695A (zh) 2021-04-16
CN114729000A (zh) 2022-07-08
AU2020304679A1 (en) 2022-01-20
CA3143545A1 (en) 2020-12-30
JP2022538301A (ja) 2022-09-01
BR112021026445A2 (pt) 2022-03-08
WO2020264512A1 (en) 2020-12-30
US20230257415A1 (en) 2023-08-17

Similar Documents

Publication Publication Date Title
MX2023002006A (es) Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central.
MX2021015854A (es) Composiciones y métodos para tratar trastornos del snc.
MX2023005099A (es) Composiciones y usos de las mismas para el tratamiento de trastornos en el sistema nervioso central.
JOP20220142A1 (ar) مثبطات kras g12c
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
PH12020550256A1 (en) 1-benzyl-2-imino-4-phenyl-5-oxoimidazolidine derivatives as hiv protease inhibitors
TN2017000374A1 (en) TGF-β INHIBITORS
PH12021550825A1 (en) Quinoline derivatives as alpha4beta7 integrin inhibitors
MX2021010122A (es) Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos.
PH12021550713A1 (en) Medicament for the treatment of chronic cough
PH12019500568A1 (en) Dopamine-b-hydroxylase inhibitors
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
MX2022004450A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1.
PH12017501422A1 (en) 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders
MX2021015942A (es) Composiciones y métodos para tratar trastornos del snc.
ZA202006071B (en) Antiproliferation compounds and uses thereof
MX2021007247A (es) Derivados de rapamicina.
MX2021012105A (es) Compuestos de pirrol.
MX2021003508A (es) Derivados de 5-azaindazol como antagonistas del receptor de adenosina.
PH12020500542A1 (en) Dopamine-b-hydroxylase inhibitors
MX2021007258A (es) Composiciones de esparsentan amorfas.
WO2022115381A8 (en) Compositions and methods for treating cns disorders
MX2021014458A (es) Compuestos triciclicos.
MX2022000729A (es) Terapia de combinacion para el tratamiento del cancer.
MX2023002539A (es) Metodos para tratar enfermedades o afecciones mediadas por fosfodiesterasa iv (pde iv).